TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has shared an update.
JCR Pharmaceuticals reported its consolidated financial results for the first quarter of FY2025, showing a 5.2% increase in net sales compared to the previous year, despite recording an operating loss of 606 million yen. The company’s financial forecast for the fiscal year ending March 31, 2026, remains unchanged, with expectations of a 14.3% increase in net sales, indicating a positive outlook for future growth.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of biopharmaceuticals and regenerative medicine products. The company is listed on the Tokyo Stock Exchange and is known for its innovative approaches in drug development and its commitment to addressing unmet medical needs.
Average Trading Volume: 1,681,127
Technical Sentiment Signal: Hold
Current Market Cap: Yen87B
See more data about 4552 stock on TipRanks’ Stock Analysis page.